Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C2654
http://purl.obolibrary.org/obo/NCIT_C2654
|
|---|---|
| Preferred Name | Ipilimumab |
| Definitions |
A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. |
|---|---|
| prefLabel | Ipilimumab
|
| label | Ipilimumab
|
| PDQ_Closed_Trial_Search_ID | 38447
|
| code | C2654
|
| Has_Target | |
| prefixIRI | NCIT:C2654
|
| in_subset |
See more
See less
|
| Display_Name | Ipilimumab
|
| Preferred_Name | Ipilimumab
|
| FDA_UNII_Code | 6T8C155666
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Ipilimumab
|
| CAS_Registry | 477202-00-9
|
| NSC Number |
720801
732442
|
| NCI_Drug_Dictionary_ID | 38447
|
| Legacy Concept Name | Anti-Cytotoxic_T-Lymphocyte-Associated_Antigen-4_Monoclonal_Antibody
|
| type | |
| ALT_DEFINITION | A monoclonal antibody being studied in the treatment of certain types of cancer. Ipilimumab is made in the laboratory and binds to the molecule CTLA-4 on T cells (a type of white blood cell). Ipilimumab may block CTLA-4 and help the immune system kill cancer cells.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38447
|
| Accepted_Therapeutic_Use_For | Unresectable or Metastatic Melanoma
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C1367202
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |